resiquimod resiquimod resiquimod (r-848) is a drug that acts as an immune response modifier, and has antiviral and antitumour activity. it is used as a topical gel in the treatment of skin lesions such as those caused by the herpes simplex virus and cutaneous t cell lymphoma, and as an adjuvant to increase the effectiveness of vaccines. in an animal disease model, systemic administration of resiquimod-loaded nanoparticles has been shown to improve response rates to cancer immunotherapy with a checkpoint inhibitor through stimulation of tumor-associated macrophages. it has several mechanisms of action, being both an agonist for toll-like receptor 7 and 8, and an upregulator of the opioid growth factor receptor. on 28 april 2016, orphan designation (eu/3/16/1653) was granted by the european commission to galderma r&d, france for resiquimod to be used in the treatment of cutaneous t-cell lymphoma. resiquimodclinical dataroutes ofadministrationtopicalatc codenonelegal statuslegal status investigational identifiers iupac name 1-quinolin-1-yl]-2-methylpropan-2-ol cas number144875-48-9 ypubchem cid159603iuphar/bps5051chemspider140330 nuniiv3dmu7pvxfchemblchembl383322 ncomptox dashboard (epa)dtxsid7040603 chemical and physical dataformulac17h22n4o2molar mass314.389 g·mol−13d model (jsmol)interactive image smiles ccocc1nc2c(n)nc3ccccc3c2n1cc(c)(c)o inchi inchi=1s/c17h22n4o2/c1-4-23-9-13-20-14-15(21(13)10-17(2,3)22)11-7-5-6-8-12(11)19-16(14)18/h5-8,22h,4,9-10h2,1-3h3,(h2,18,19) nkey:bxnmtoqrybfhnz-uhfffaoysa-n n ny (what is this?) (verify)